search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • Print
  • ShareThis
  • Text Size
  • NIH Member Spotlight: Dr. Henry M. Blumberg

    Principal Investigator, Ethiopia-Emory TB Research Training Program and Emory-Georgia TB Research Training, Emory University, Atlanta, GA

    Henry M. Blumberg headshot

    Dr. Henry M. Blumberg is an infectious disease physician scientist specializing in tuberculosis (TB) research. He is a Professor of Medicine, Epidemiology, and Global Health at Emory University, and is the Director of the Clinical and Translational Research Training Programs at Emory and the Atlanta Clinical and Translational Science Institute.

    Dr. Blumberg’s NIH Fogarty-supported research

    Dr. Blumberg serves as Principal Investigator for Fogarty International Center Global Infectious Diseases grants focused on TB research and research training in Ethiopia and Georgia, and has served as lead investigator and collaborator for the Medical Education Partnership Initiative Junior Faculty Research Training program in Ethiopia to Addis Ababa University.

    The Ethiopia-Emory TB Research Training Program and the Emory-Georgia TB Research Training Program provides TB research training for promising Ethiopian and Georgian investigators to build skills and capacity to carry out international TB-related research and improve the public health infrastructure for TB control, including research aimed at reducing the risk of drug-resistant tuberculosis. U.S. investigators have greatly benefited from these collaborations, which have enhanced their career development and facilitated research grant awards to move the field forward.

    The Medical Education Partnership Initiative scholars program through Fogarty International Center and President’s Emergency Plan for AIDS Relief enhances research capacity at Addis Ababa University by training core faculty to fill in critical knowledge and implementation gaps in disciplines that reflect priority health challenges in Ethiopia, such as HIV and related infections, maternal and child health, and non-communicable diseases that include diabetes and cardiovascular conditions.

    Impact on patients and public health

    Tuberculosis is the leading infectious disease cause of death globally. Research to reduce tuberculosis cases and deaths and to develop vaccines, new drugs, and diagnostics must be conducted in regions with a high burden of disease. This training and resulting research has the promise of addressing and reducing the incidence of drug-resistant tuberculosis, a growing worldwide threat. Training researchers in low- and middle-income countries strengthens the public health infrastructure, facilitates prompt responses to outbreaks and epidemics, and contributes to better health outcomes and more stable and secure communities.

| HIVMA | Contact Us

© Copyright IDSA 2017 Infectious Diseases Society of America

Full Site Mobile Site